Comparison of Transforming Growth Factor-Beta 1 Concentration in Preeclampsia and Normal Pregnancy Women

Yusrawati Yusrawati, Dyka Aidina, Eti Yerizel

Abstract


BACKGROUND: According to the theory of endothelial dysfunction, the pathogenesis of preeclampsia is associated with the imbalance of angiogenic and anti-angiogenic factors. Transforming growth factor-beta 1 (TGF-β1) has also proposed as a proangiogenic factor that influences preeclampsia. This study was conducted to compare a mean difference of TGF-β1 between preeclampsia and normal pregnancy.

METHODS: This study was an observational crosssectional study with 25 subjects of pregnant women with preeclampsia and 25 subjects of normotensive pregnant women. The study was conducted in Dr. Reksodiwiryo Hospital, Bhayangkara Hospital, and Dr. Rasidin Hospital in Padang, Indonesia from October 2015 to January 2016. For the determination of TGF-β1 concentration, peripheral Abstract venous blood samples were taken. The blood samples were analyzed by enzyme-linked immunosorbent assay (ELISA) in Biomedical Laboratory, Faculty of Medicine, Andalas University. The mean difference was statically analyzed by independent samples T-test.

RESULTS: The mean difference of TGF-β1 was lower in preeclampsia group than normal pregnancy group (2.02±0.99 ng/mL vs. 3.24±2.67 ng/mL; p<0.05).

CONCLUSION: The TGF-β1 concentration was lower in pregnant women with preeclampsia. Thus, it may have a role as a marker in preeclampsia.

KEYWORDS: preeclampsia, normal pregnancy, transforming growth factor-beta1, TGF-β1


Full Text:

PDF

References


Bender RM, Ryan GL. Pre-eclampsia and eclampsia: global challenges in low resource settings complete with proposed interventions in rural Haiti. Proc Obstet Gynecol. 2013; 3: 1-6, article.

Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009; 33: 130-7,

Keman K, Prasetyorini, Langgar MJ. Perbandingan eksprei p53, ">CrossRef.Bcl-2, dan indeks apoptosis trofoblas pada preeklampsia/eklampsia dan kehamilan normal. Maj Obstet Ginekol Indones. 2009; 33: 151-9, article.

Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluable endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006; 355: 992-1005, CrossRef.

Maynard SE, Karumanchi A. Angiogenic factors and preeclampsia. Semin Neprol. 2011; 31: 33-46, CrossRef.

Bilezikjian LM, Blount AL, Donaldson CJ, Vale WW. Ptuitary actions of ligands of the TGF-beta family:activins and inhibins. Reproduction. 2006; 132: 207-15, CrossRef.

Chen Q, Chen L, Liu B, Vialli C, Stone P, Ching LM, Chamley L. The role of autocrin TGFβ1 in endothelial cell activation induced by phagocytosis of necrotic trophoblasts:a possible role in the pathogenesis of pre-eclampsia. J Pathol. 2010; 221: 87-95, CrossRef.

Hennesy A, Orange S, Willis N, Painter DM, Child A, Horvath JS. Transforming growth factor-β1 does not relate to hypertension in pre-eclampsia. Clin Exp Pharmacol Physiol. 2002; 29: 968-71, CrossRef.

Li X, Shen L, Tan H. Polymorphisms and plasma level of transforming groowth factor-beta 1 and risk for preeclampsia: a systematic review. PlosS ONE. 2014; 9: e97230, CrossRef.

Enquobahrie DA, Williams MA, Qiu C, Woelk GB, Mahomed K. Maternal plasma transforming growth factor-β1 concentrations in preeclamptic and normotensive pregnant Zimbabwean women. J Maternal Featl Neonatal Med. 2005; 17: 343-8, CrossRef.

Clausen T, Djurovic S, Resesland JE, Berg K, Drevon CA, Henriksen T. Altered plasma concentration of leptin, transforming growth afctor-β1 and plasminogen activator inhibitor type 2 at 18 weeks of gestation in women destined to develop pre-eclampsia. Circulating markers of disturbed placentation? Placenta. 2002; 23: 380-5, CrossRef.

Lim JH, Kim SY, Park SY, Lee MH, Yang JH, Kim MY, et al. Soluble endoglin and transforming growth factor-β1 in women who subsequently developed preeclampsia. Prenat Diagn. 2009; 29: 471-6, CrossRef.

Santibanez J, Quintanilla M, Bernabeu. TGF-β receptor system and its role in physiological and pathological conditions. Clin Sci. 2011; 121: 233-51, CrossRef.

Robinson CJ, Johnson DD. Soluble endoglin as a second trimester marker for preeclampsia. Am J Obstet Gynecol. 2007; 197: 174.e1-5, CrossRef.

Muy-Rivera M, Sanchez SE, Vadachkoria S, Qiu C, Bazul V, Williams MA. Transforming growth factor-β1 in plasma is associated with preeclampsia risk in Peruvian women with systemic inflammation. Am J Hypertens. 2004; 17: 334-8, CrossRef.

Naicker T, Khedun SM, Moodley J. Transforming growth factor β1 levels in platelet depleted plasma in African women with preeclampsia. J Obstet Gynecol. 2002; 22: 279-82, CrossRef.




DOI: http://dx.doi.org/10.18585/inabj.v9i1.310

Accreditation and Index by:

            

 

©2017, The Prodia Education and Research Institute. All rights reserved.